Home > MAO  & Histone Demethylase & > Tranylcypromine HCl

Tranylcypromine HCl

盐酸环苯丙胺,SKF-385,2-PCPA HCl

Tranylcypromine hydrochloride is a racemic mixture of (±)-Trans-2-phenylcyclopropyl-1-amine (TCP, tPCPA) · HCl that covalently inhibits the LSD and MAO enzymes. Tranylcypromine (2-PCPA) HCl是一种非选择性的不可逆的单胺氧化酶(MAO)抑制剂,用作抗抑郁药和抗焦虑药。

目录号
EY0405
EY0405
纯度
99.17%
99.17%
规格
50 mg
100 mg
原价
240
470
售价
240
470
库存
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Tranylcypromine HCl is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). IT inhibits histone demethylation. In combination with CHIR 99021, enables reprogramming of mouse embryonic fibroblasts transduced by only two factors, Oct4 and Klf4, into induced pluripotent stem (iPS) cells.

    Inhibitionof tranylcypromine (tPCPA) · HCl for LSD and MAO enzymes[1]

    Inhibition of tranylcypromine (TCP) for thereuptake of norepinephrine


    MAOinhibition of tranylcypromine in tissue homogenates[4]

    Inhibitionof tranylcypromine for LSD and MAO enzymes[5]

    Inhibition of tranylcypromine (TCP) for P450sin human liver microsomes[6]

    Theinhibition of tranylcypromine against human CYP isoforms[6]


  • 体外研究

  • 体内研究

  • 激酶实验

    Determinationof MAO activity[4]

    MAO assay was performed utilizing themeasurement of deaminated14C-metabolites of14C-labelledMAO substrates. In a typical protocol 10μl enzymepreparation [homogenates containing 1- 5μg protein in0.1mol/L phosphate buffer (pH 7.4)], 10μl 0.1mol/Lphosphate buffer containing the MAO inhibitors in the respective experimentsand 20μl MAO substrate in 0.1mol/L phosphate buffer labelled with 100μmol/L5-[2-14C]hydroxytryptamine (1.6Ci/mol, 15,000cpm), 100μmol/L[1-14C]tyramine (1.6Ci/mol, 15,000cpm) or 10μmol/L 2-[l-14C]phenylethylamine(12.6Ci/mol, 15,000cpm) were mixed in a glass-stoppered centrifuge tube andincubated for 20 min at 37oC. In control experiments the reactionwas found to be linear up to 30 min of incubation. In experiments for the determinationof the km-values concentrations of the labeled substrates (15,000cpm) andaccordingly of the specific activities were varied as described in the resultssection. The reaction was stopped by addition of 100μl 2N HCl and deaminated14C-metabolites were extracted into 6ml toluene-ethylacetate (1:1).After centrifugation, a 4 ml aliquot of the organic layer was transferred to avial containing 5 ml scintillation liquid and counted in a liquid scintillationspectrophotometer. The counting efficiency was 95.6%. Specific activity wasexpressed as nmol substrate deaminated per mg protein and per min.

  • 细胞实验

    Cellculture[8]

    Human prostate carcinoma cells (LNCaP-LN3)were grown in MEM, supplemented with 10% fetal bovine serum, penicillin (100U/ml)/streptomycin (100μg/ml) at 37˚C in a 5% CO2atmosphere.

    Cellproliferation assay

    The proliferation of LNCaP-LN3 cells wasevaluated using a Premix WST-1 Cell Proliferation Assay System. After exposingthe cells to pargyline or tranylcypromine (0.5, 1, 1.5 or 2mM) for 24, 48, 72,96 or 120 h, the culture medium was removed and the cells were washed withphosphate buffered saline (PBS). WST-1 reagent was then added, and the cells wereincubated for 4 h. The results of the WST-1 assay were measured using a Model680 microplate reader.

  • 动物实验

    Animaltreatments[9]

    Adult rats received one, three or fivedaily tranylcypromine (3 mg/kg, i.p.) injections timed so that the lastinjection occurred 20 h or 1 h prior to sacrifice and removal of their brains.Saline groups received one, three or five injections (1.5 ml/kg, i.p.)similarly timed, but with no difference between pretreatment times, they werecombined. The number of injections was chosen according to behavioral data:rats began to prefer the reinforced hole on day 3 and this effect wassignificant on day 5.

    Tissuepreparation

    Male rats were decapitated, their brainsremoved immediately and homogenized in 8 ml of 50mM sodium phosphate buffer(PB), pH 7.4. Homogenates were centrifuged at 600xg for 10min at 4oC, and the resulting supernatants were diluted with PB to afinal tissue concentration of 20 mg/ml. Samples (100 ml) were taken foranalysis of protein content using a Bradford protein assay. The remainingtissue samples were used for enzymatic analysis of MAO-A and -B activitiesusing a radiochemical assay, slightly modified from established procedures. Briefly,100 ml tissue aliquot was incubated in a reaction volume of 1 ml PB buffer,pH7.4, with [14C]serotonin (5-HT)

    or [14C]phenylethylamine (PEA)for measurement of MAO-A and MAO-B activities, respectively. Radioligands weresupplemented with addition of unlabeled ligand to yield a final concentrationof 1 mM within the assay mixture. Blanks were prepared in the same manner but omittingbrain homogenate. After incubation for 20 min at 37oC, reactionswere terminated by cooling on ice and addition of 100 ml of 6N HCl. Thedeaminated products were extracted from the assay mixture by the addition of 6ml of benzene/ethyl acetate for [14C]5-HTand 6 ml of toluene for [14C]PEAand vortexed for 30 s. Tubes were centrifuged for 7 min at 1400 x g to separatethe organic and inorganic phases. Four ml of the organic layer was removed andadded to 5 ml of Safety-Solve scintillation fluid for scintillation counting.Data were reported as pmol/mg protein/min.

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Binda C VS, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, Edmondson DE, Minucci S, Mattevi A, Mai A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc. . 2010 132(19):6827-6833.
    [2] Horn AS SS. Steric requirements for catecholamine uptake by rat brain synaptosomes: studies with rigid analogs of amphetamine. J Pharmacol Exp Ther. . 1972;180(3):523-530.
    [3] Lotfipour S, Arnold MM, Hogenkamp DJ, Gee KW, Belluzzi JD, Leslie FM. The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition. Neuropharmacology. 2011;61(1-2):95-104.
    [more]

    分子式
    C9H12ClN
    分子量
    169.65
    CAS号
    1986-47-6
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    100 mM
    Water
    100 mM
    Ethanol

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT01430455 Bipolar Disorder I or II Drug: Tranylcypromine New York State Psychiatric Institute Phase 4 2011-05-01 2011-12-14
    NCT00653393 To Determine the Bioavailability of Tranylcypromine Drug: Tranylcypromine|Drug: Parnate Par Pharmaceutical, Inc.|SFBC Ft. Myers, Inc Phase 1 2004-10-01 2008-04-03
    NCT00296686 Major Depression Drug: Tranylcypromine|Drug: Dextroamphetamine|Drug: Triiodothyronine New York State Psychiatric Institute Phase 4 2001-09-01 2012-04-26
    NCT02717884 Acute Myeloid Leukemia|Myelodysplastic Syndrome Drug: tranylcypromine|Drug: all-trans retinoic acid|Drug: cytarabine Ulrike Kohlweyer|University Hospital Freiburg Phase 1|Phase 2 2015-05-01 2016-06-01
    NCT01031810 Major Depressive Disorder Drug: tranylcypromine New York State Psychiatric Institute|National Institute of Mental Health (NIMH) Phase 4 2009-11-01 2014-09-15
    NCT02273102 Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Leukemia Drug: Tranylcypromine|Drug: Tretinoin University of Miami Phase 1 2015-03-02 2017-03-07
    NCT03044184 Stroke Hemorrhagic|Intracerebral Haemorrhage Drug: Tranexamic Acid Kwong Wah Hospital Phase 3 2017-04-01 2017-02-04
    NCT01643135 Bleeding Drug: tranexamic acid|Drug: 0.9% NaCl Mahidol University Phase 4 2012-06-01 2013-12-17
    NCT00612807 Major Depressive Disorder|Partner Relational Disorder (V61.10) Behavioral: Weekly marital therapy|Drug: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc. Duke University|National Institutes of Health (NIH) Phase 1|Phase 2 2006-07-01 2013-06-17
    NCT00223691 Autonomic Failure|Orthostatic Hypotension Drug: Atomoxetine|Drug: Acarbose|Drug: Pyridostigmine Bromide|Drug: Yohimbine|Drug: Midodrine HCl|Drug: placebo|Drug: Modafinil|Drug: Octreotide|Other: water intake|Drug: Diphenhydramine Hydrochloride|Drug: Ranitidine HCL|Drug: Tranylcypromine|Drug: Ergotamine/ Caffeine|Drug: Celecoxib|Drug: Pseudoephedrine|Drug: Methylphenidate|Drug: Indomethacin|Drug: Ibuprofen|Drug: Oxymetazoline 0.05% nasal solution|Dietary Supplement: Bovril|Drug: Acetazolamide|Drug: Rivastigmine tartrate|Drug: Carbidopa/levodopa|Device: Inflatable abdominal binder|Device: inflatable abdominal binder (sham) Vanderbilt University|Vanderbilt University Medical Center Phase 1 2002-03-01 2017-01-16
    NCT01896349 Treatment Resistant Depression Other: IPT+ antidepressant drugs|Drug: fluoxetine|Drug: sertraline|Drug: paroxetine|Drug: Citalopram|Drug: escitalopram|Drug: fluvoxamine|Drug: Venlafaxine|Drug: Duloxetine|Drug: Bupropion|Drug: Lithium|Drug: Risperidone|Drug: tranylcypromine|Drug: Imipramine|Drug: amitriptyline|Drug: Clomipramine|Drug: nortriptyline|Drug: trazodone|Drug: Mirtazapine|Drug: sulpiride Hospital de Clinicas de Porto Alegre 2013-04-01 2013-07-10
    NCT02458729 Osteoarthritis, Knee Drug: Tranexamic Acid 5%,5ml/amp (intraoperative)|Drug: Tranexamic Acid 5%,5ml/amp (3 hours after operation)|Drug: 0.9% Normal Saline (intraoperative)|Drug: 0.9% Normal Saline (3 hours after operation)|Drug: rivaroxaban (10mg) Chang Gung Memorial Hospital Phase 4 2012-08-01 2015-05-28
    NCT02453802 Osteoarthritis, Knee Drug: Tranexamic Acid 5%,5ml/amp|Drug: Tranexamic Acid 5%,5ml/amp|Drug: rivaroxaban (10mg)|Drug: 0.9% Normal Saline|Drug: 0.9% Normal Saline Chang Gung Memorial Hospital Phase 4 2015-06-01 2015-05-26
    NCT00994994 Blood Loss|Congenital Heart Disease Drug: Tranexamic Acid Okayama University 2006-01-01 2009-10-13
    NCT02865174 Osteoarthritis, Knee Drug: Topical tranexamic acid|Drug: Floseal庐|Drug: Enoxaparin Chang Gung Memorial Hospital Phase 4 2016-09-01 2016-08-09
    NCT00704860 Major Depression Other: Open label pharmacotherapy University of Ottawa Phase 4 2005-02-01 2011-01-18
    NCT01713101 Acute Upper Gastrointestinal Hemorrhage Drug: Early intravenous tranexamic acid administration|Drug: placebo Seoul National University Hospital Phase 3 2012-10-01 2014-05-14

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :